profit from every $100 of sales.
$0$100
Anixa Biosciences
$3.16-0.47% today
-24.6% in 1 year
1-year low $2.351-year high $5.22
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Anixa Biosciences sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$10.9 million of profit last year.
SalesProfit
Anixa Biosciences vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Anixa Biosciences | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads Anixa Biosciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| 0 | 0 | 0 | – | |
| -14 | -11 | -14 | -12 | |
| -14 | -11 | -14 | -12 | |
| -14 | -10 | -13 | -11 | |
| -0.45 | -0.32 | -0.39 | -0.34 | |
| – | 23.3% | – | – | |
| – | -5,243.3% | – | – | |
| – | -4,671.9% | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 30 | 26 | 22 | 16 |
| Cash | 12 | 1 | 1 | 1 |
| Total debt | 0 | 0 | 0 | 0 |
| Total liabilities | 2 | 2 | 3 | 2 |
| 29 | 24 | 20 | 15 | |
| 30 | 31 | 32 | 32 | |
| -37.5% | -35.5% | -54.0% | -60.2% | |
| -46.8% | -40.3% | -62.8% | -72.1% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -6 | -6 | -7 | -7 | |
| – | – | – | – | |
| -6 | -6 | -7 | -7 | |
| Dividends paid | – | – | – | – |
| – | 0 | 0 | 0 | |
| 6 | 4 | 4 | 4 |
Valuation
- –
- –
- –
- 6.0×
- 523.1×
- –
- –
- -5.7%
- -8.9%
- 0.0%
Profitability
- 23.3%
- -5,243.3%
- -4,671.9%
- 0.0%
- -78.6%
- -51.2%
- -65.6%
- -67.7%
- -78.8%
- –
Growth
- –
- –
- +2.2%
- –
- +3.2%
Financial health
- -0.1×
- 0.01
- 1.3%
- –
- 12.18
- 12.18
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 948
Bottom 18%of 985
What analysts expect
- Average price target
- $5.83
- Range
- $3.50 – $10.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Mar 9, 2026 | -0.08 | -0.09 | +11.1% |
| Jan 12, 2026 | -0.09 | -0.09 | −2.3% |
| Sep 10, 2025 | -0.07 | -0.10 | +30.0% |
| May 28, 2025 | -0.09 | -0.10 | +10.0% |
| Mar 11, 2025 | -0.10 | -0.10 | +0.0% |
| Jan 10, 2025 | -0.09 | -0.11 | +18.2% |
| Sep 6, 2024 | -0.10 | -0.11 | +9.1% |
| Jun 4, 2024 | -0.10 | -0.11 | +9.1% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
26No pass
Benjamin Graham
40No pass
Philip Fisher
35No pass
Peter Lynch
10No pass
Joel Greenblatt
0No pass
Charlie Munger
30No pass
Terry Smith
22No pass
Questions about Anixa Biosciences
Is Anixa Biosciences a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Anixa Biosciences AI analysis
What does Anixa Biosciences do?
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. It is in Biotechnology.
Does Anixa Biosciences pay a dividend?
No. Anixa Biosciences does not pay a dividend at the moment.
Is Anixa Biosciences stock halal?
Yes. Anixa Biosciences passes our halal screen: its business is permitted and its debt is 0.2% of its market value, under the 30% limit. How we check
How has Anixa Biosciences stock done over the past year?
Down 24.6% over the past twelve months, to $3.16. It traded between $2.35 and $5.22 and is 39.5% below its high.
Who are Anixa Biosciences's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Anixa Biosciences's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.